关注
Ozkan Gelincik
Ozkan Gelincik
Weill Cornell Medicine
在 med.cornell.edu 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Recurrent frameshift neoantigen vaccine elicits protective immunity with reduced tumor burden and improved overall survival in a Lynch syndrome mouse model
J Gebert, O Gelincik, M Oezcan-Wahlbrink, JD Marshall, ...
Gastroenterology, 2021
782021
Proteomic characterization of outer membrane vesicles from gut mucosa-derived fusobacterium nucleatum
J Liu, CL Hsieh, O Gelincik, B Devolder, S Sei, S Zhang, SM Lipkin, ...
Journal of proteomics 195, 125-137, 2019
612019
Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa
L Reyes-Uribe, W Wu, O Gelincik, PV Bommi, A Francisco-Cruz, LM Solis, ...
Gut 70 (3), 555-566, 2021
452021
ETHE1 overexpression promotes SIRT1 and PGC1α mediated aerobic glycolysis, oxidative phosphorylation, mitochondrial biogenesis and colorectal cancer
M Witherspoon, D Sandu, C Lu, K Wang, R Edwards, A Yeung, O Gelincik, ...
Oncotarget 10 (40), 4004, 2019
212019
Inhibition of colorectal cancer genomic copy number alterations and chromosomal fragile site tumor suppressor FHIT and WWOX deletions by DNA mismatch repair
S Jahid, J Sun, O Gelincik, P Blecua, W Edelmann, R Kucherlapati, ...
Oncotarget 8 (42), 71574, 2017
82017
Abstract 2732: Frameshift neoantigen vaccination prevent Lynch syndrome mouse model intestinal cancer
O Gelincik, H Ibrahim, M Ozkan, A Ahadova, S Sei, R Shoemaker, M Kloor, ...
Cancer Research 79 (13 Supplement), 2732-2732, 2019
52019
Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model (vol 161, pg 1288, 2021)
J Gebert, O Gelincik, M Oezcan-Wahlbrink
Gastroenterology 161 (6), 2070-2070, 2021
22021
Frameshift mutations in peripheral blood as a biomarker for surveillance of Lynch syndrome
Y Song, H Loomans-Kropp, RN Baugher, B Somerville, SS Baxter, ...
JNCI: Journal of the National Cancer Institute 116 (6), 957-965, 2024
2024
Abstract CT111: Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa
LR Uribe, W Wu, O Gelincik, PV Bommi, A Francisco-Cruz, LM Solis, ...
Cancer Research 80 (16 Supplement), CT111-CT111, 2020
2020
Proteomic characterization of outer membrane vesicles from gut mucosa-derived fusobacterium nucleatum (vol 8, pg 125, 2019)
J Liu, CL Hsieh, O Gelincik, B Devolder, S Sei, S Zhang, SM Lipkin, ...
JOURNAL OF PROTEOMICS 200, 161-161, 2019
2019
Immunoprevention of Lynch syndrome mouse model intestinal cancer with recurrent neoantigen vaccination
Ö Gelincik, M Kloor, M Özcan, A Ahadova, Y Yuan, H Ibrahim, S Sei, ...
2019
Abstract 717: Mouse model for the development of preventive and therapeutic vaccines against microsatellite-unstable cancers
M Kloor, M Oezcan, A Ahadova, Y Yuan, P Bork, S Sei, R Shoemaker, ...
Cancer Research 78 (13 Supplement), 717-717, 2018
2018
系统目前无法执行此操作,请稍后再试。
文章 1–12